Advanced acellular dermal matrix technology from Atlantic cod skin to promote superior wound healing outcomes
Kerecis pioneered the use of intact Atlantic cod fish skin from Iceland as an advanced acellular dermal matrix scaffold for superior wound management and tissue regeneration.
Unlike mammalian-derived grafts, Kerecis products are derived from intact Atlantic cod fish skin harvested from sustainable fisheries in Iceland. The gentle decellularization process preserves the natural three-dimensional architecture of collagen, elastin, and glycosaminoglycans—creating a true extracellular matrix that promotes rapid cellular ingrowth and neovascularization.
Kerecis works through multiple biological pathways to accelerate wound closure and tissue quality.
Acts as a three-dimensional acellular dermal matrix that provides architectural support for host cell infiltration, collagen deposition, and vascular network formation.
Omega-3 polyunsaturated fatty acids (DHA and EPA) activate specialized pro-resolving mediator (SPM) pathways that reduce IL-1β production from macrophages, decreasing inflammation while promoting healing.
The natural porosity and bioactive properties of fish skin stimulate rapid blood vessel formation, restoring oxygen and nutrient delivery to wounded tissues.
Provides an immediate protective barrier against contamination and infection while the wound transitions from the inflammatory to proliferative phase.
Five specialized product lines engineered for specific clinical indications and wound characteristics.
Flagship product for chronic wound management including diabetic foot ulcers, venous leg ulcers, and pressure ulcers.
Variants: Solid, Micro, Fenestrated, Expanse
Specialized for surgical and trauma wounds including post-Mohs wounds, donor sites, and surgical defects.
Variants: Standard, Silicone, Micro, Meshed 2:1
Optimized for burn wound management including second-degree and full-thickness burns with enhanced scar quality outcomes.
Variants: Solid, Micro, Mano (hand-shaped), Meshed 2:1
Specifically designed for diabetic foot ulcers with integrated silicone contact layer to reduce pain and optimize moisture management.
Variants: Standard, Adhesive, Spiral
For soft tissue reinforcement, tendon protection, and complex surgical reconstructions requiring structural support.
Application: Soft tissue barrier and protection
Recent published studies demonstrate superior healing outcomes and safety profiles across multiple wound types.
Kerecis products are indicated for a wide spectrum of acute and chronic wounds.
| Wound Category | Specific Indications | Recommended Product Line |
|---|---|---|
| Chronic Wounds | Diabetic foot ulcers, venous leg ulcers, pressure ulcers, stasis ulcers | MariGen (primary), Shield (DFU specific) |
| Surgical Wounds | Donor sites, post-Mohs micrographic surgery defects, podiatric surgery, trauma lacerations | SurgiClose, SurgiBind |
| Partial & Full-Thickness | Partial-thickness wounds, full-thickness skin defects | MariGen (chronic), SurgiClose (acute) |
| Burn Wounds | Second-degree (partial-thickness) burns, full-thickness burns, thermal injuries | GraftGuide (primary burn treatment) |
| Trauma & Acute Wounds | Abrasions, skin tears, puncture wounds, laceration repair | SurgiClose, MariGen |
| Tendon & Soft Tissue | Tendon injuries, soft tissue reinforcement, surgical reconstruction | SurgiBind |
| Complex Wounds | Ischemic wounds, infected wounds (post-cleansing), refractory wounds | MariGen with adjunctive therapy |
Kerecis offers distinct biological and clinical advantages compared to mammalian grafts and synthetic alternatives.
Kerecis uses a proprietary gentle decellularization process on Atlantic cod fish skin harvested from sustainable fisheries in Iceland. The process removes all cellular components while preserving the native three-dimensional extracellular matrix architecture, including collagen, elastin, and glycosaminoglycans. This preservation of natural structure is critical to the product's biological activity and the retention of omega-3 polyunsaturated fatty acids (EPA and DHA). The intact matrix provides superior scaffolding for cellular infiltration and neovascularization compared to other acellular dermal matrices.
This is an important consideration that should be discussed with the treating clinician. The decellularization process removes cellular proteins that typically trigger allergic responses. However, patients with severe fish allergies should inform their healthcare provider before treatment. The risk of systemic allergic reaction is minimal since the product is applied topically to the wound rather than ingested, and the decellularization removes allergen-containing cells. Your wound care specialist can assess individual risk factors and determine appropriate precautions or alternative treatments if needed.
Application depends on the specific wound type and product variant. Generally, Kerecis products are applied directly to a clean, debrided wound bed. For chronic wounds like diabetic foot ulcers, MariGen or Shield is placed on the prepared wound surface, often with appropriate wound dressing coverage to maintain a moist healing environment. For burns and surgical wounds, the tissue is placed as a graft covering. Some variants come with silicone contact layers (Shield, SurgiClose Silicone) that remain adherent to the wound, while others are integrated into dressings. Your wound care specialist will determine the specific application protocol based on your wound characteristics and clinical situation. Detailed application instructions accompany each product box.
Kerecis products are supplied either as fresh or ready-to-use formulations with varying shelf lives based on the specific product variant. Fresh products typically have 21-day shelf life when stored in specialized preservative solutions at specific temperature ranges (typically 2-8°C). Ready-to-use products may have extended shelf life. Storage conditions are critical to maintaining product viability and therapeutic properties. Detailed storage instructions and shelf life information are provided with each product. Always check packaging for specific storage requirements and expiration dates. Proper storage maintains the structural integrity and bioactive properties of the fish skin matrix.
Kerecis products have FDA clearance as acellular dermal matrices and are covered by most major insurance plans, including Medicare and Medicaid, for appropriate clinical indications. Coverage determination depends on factors including diagnosis, wound characteristics, evidence of standard care failure or contraindications, medical necessity documentation, and specific insurance plan policies. Your healthcare provider's office typically handles insurance verification and pre-authorization when needed. Coverage may vary by specific product variant and clinical indication. Sunspot Medical Group can assist with insurance questions and can help facilitate the authorization process for patients in our service area. We recommend contacting your insurance provider or our office for specific coverage details.
41.6% healing in DFUs vs. 22.2% standard care. 82% success in ischemic wounds. 100% healing when combined with NPWT.
26% faster burn healing (17 days vs. 23 days). Rapid neovascularization through natural porosity.
0.88% infection rate across 114 patients. No autoimmune response. FDA-cleared since 2013.
Natural omega-3 fatty acids activate anti-inflammatory pathways. Multi-mechanism action beyond passive scaffolding.
Atlantic cod fish skin from sustainable Icelandic fisheries. Environmentally responsible sourcing.
FDA-cleared acellular dermal matrix covered by Medicare, Medicaid, and most insurance plans.
Contact Sunspot Medical Group in Las Cruces, NM to discuss Kerecis products for your patients or facility.
Request Product InformationPatient Disclaimer: Kerecis fish skin grafts and acellular dermal matrices are prescription medical devices that should only be used under the direction of a qualified healthcare provider. The information on this page is for educational purposes and does not constitute medical advice. Individual suitability, appropriate use, contraindications, and safety considerations vary by patient and should be thoroughly discussed with your healthcare provider. Clinical outcomes depend on proper application technique, appropriate wound selection, patient factors, and comprehensive wound care management. Please consult your healthcare provider to determine if Kerecis products are appropriate for your specific condition.
Healthcare providers and facilities in Las Cruces and surrounding areas can contact us for product samples, ordering information, and clinical support.